Sökning: onr:"swepub:oai:DiVA.org:uu-489962" >
Ixovex-1, a novel o...
-
Anwar, MohiemenChelsea & Westminster NHS Fdn Trust, ENT Dept, London, England.
(författare)
Ixovex-1, a novel oncolytic E1B-mutated adenovirus
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
-
2022-05-20
-
Springer Nature,2022
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-489962
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-489962URI
-
https://doi.org/10.1038/s41417-022-00480-3DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
There is a great demand for improved oncolytic viruses that selectively replicate within cancer cells while sparing normal cells. Here, we describe a novel oncolytic adenovirus, Ixovex-1, that obtains a cancer-selective replication phenotype by modulating the level of expression of the different, alternatively spliced E1B mRNA isoforms. Ixovex-1 is a recombinant adenovirus that carries a single point mutation in the E1B-93R 3' splice acceptor site that results in overexpression of the E1B-156R splice isoform. In this paper, we studied the characteristics of this novel oncolytic adenovirus by validating its in vitro behaviour in a panel of normal cells and cancer cells. We additionally studied its anti-tumour efficacy in vivo. Ixovex-1 significantly inhibited tumour growth and prolonged survival of mice in an immune-deficient lung carcinoma tumour implantation model. In complementation experiments, overexpression of E1B-156R was shown to increase the oncolytic index of both Ad5wt and ONYX-015. In contrast to prior viruses of similar type, Ixovex-1 includes a functional E3B region for better in vivo efficacy. Throughout this study, the Ixovex-1 virus has been proven to be superior in competency compared to a virus with multiple deletions.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Arendt, Maja-LouiseUniv Copenhagen, Dept Vet Clin Sci, Copenhagen, Denmark.
(författare)
-
Ramachandran, Mohanraj,1988-Uppsala universitet,Cancerimmunterapi(Swepub:uu)mohra272
(författare)
-
Carlsson, AnetteUppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi(Swepub:uu)aca31040
(författare)
-
Essand, MagnusUppsala universitet,Cancerimmunterapi(Swepub:uu)magnessa
(författare)
-
Akusjärvi, Göran,1953-Uppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi(Swepub:uu)gak30132
(författare)
-
Alusi, GhasanIxogen Ltd, London, England.
(författare)
-
Öberg, DanielUppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi(Swepub:uu)daobe475
(författare)
-
Chelsea & Westminster NHS Fdn Trust, ENT Dept, London, England.Univ Copenhagen, Dept Vet Clin Sci, Copenhagen, Denmark.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Cancer Gene Therapy: Springer Nature29:11, s. 1628-16350929-19031476-5500
Internetlänk
Hitta via bibliotek
Till lärosätets databas